For patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (allo-HCT), machine learning (ML) ...
Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.
In part 3 of a discussion with Andrew Kuykendall, MD, Moffitt Cancer Center, he talks of rusfertide’s ability to enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback